chrisvoncsefalvay/vaers-outcomes huggingface dataset:
STARTED 1.5 HOURS AFTER VACCINATION. BURNING AT SITE. TRAVELED UP SHOULDER, NECK, CHECK, AROUND EAR, SIDE OF HEAD, AND EYE. AREA BURNING THEN WENT NUMB AND LOST SENSE OF HEARING IN THAT EAR. HEARING RETURNED WITHIN 24 HOURS. AREA STILL NUMB. NEVER HAD FEVER OR OTHER SYMPTOMS. OTHERWISE FEELS FINE. PT STATES SYSTEMS IMPROVED EXCEPT SKIN IS STILL NUMB TO THE TOUCH. REACTION REPORTED BY PATIENT'S SPOUSE TODAY 1/20/21 AT 11:58 AM IN PERSON AT THE CCHD.
blood clot in his lung; This spontaneous case was reported by a consumer and describes the occurrence of PULMONARY THROMBOSIS (blood clot in his lung) in a 54-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PULMONARY THROMBOSIS (blood clot in his lung) (seriousness criterion medically significant). At the time of the report, PULMONARY THROMBOSIS (blood clot in his lung) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Magnetic resonance imaging: blood clot in lung (abnormal) Blood clot in lung.         No concomitant medication was mentioned. No treatment medication was mentioned.  Company comment: This is a spontaneous case concerning a 54 year-old, male patient with no relevant history reported, who experienced the unexpected serious event of PULMONARY THROMBOSIS. The event occurred approximately after the 2nd dose of mRNA-1273 Moderna vaccine (date of vaccination and onset date of event were not provided). The rechallenge was not applicable (information about more new doses was not available). very limited information regarding the medical history of the patient and the event was provided. The benefit-risk relationship of mRNA-1273 Moderna vaccine is not affected by this report. Further information was requested; Sender's Comments: This is a spontaneous case concerning a 54 year-old, male patient with no relevant history reported, who experienced the unexpected serious event of PULMONARY THROMBOSIS. The event occurred approximately after the 2nd dose of mRNA-1273 Moderna vaccine (date of vaccination and onset date of event were not provided). The rechallenge was not applicable (information about more new doses was not available). very limited information regarding the medical history of the patient and the event was provided. The benefit-risk relationship of mRNA-1273 Moderna vaccine is not affected by this report. Further information was requested
It was reported in a published article that a male child with a history of premature birth and a severe case of varicella at 13 months old who in approximately 8/97, a few weeks following the varicella, was vaccinated with a dose of MMR (second generation). Subsequently the patient lost the speech he had acquired and was diagnosed with autism which his neurologist attributes to chicken pox vasculitis. Upon internal review, autism was determined to be an other important medical event (OMIC). No further information is available.
Congestion; Flush; Low grade fever; Headache; Upset stomach; Dizzy - comes and goes; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 11May2021 at 13:15 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no allergy to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included sertraline (MANUFACTURER UNKNOWN) on an unknown date, for an unknown indication and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 16Apr2021 at 09:30 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 12May2021 at 00:00, the patient experienced congestion, flush, low grade fever, headache, upset stomach, dizzy that comes and goes and fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care.  Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the events congestion, flush, low grade fever, headache, upset stomach, dizzy - comes and goes and fatigue were not resolved at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Vaccines given at approximately 14:00. Crying began at approximately 18:00, at which time, infant Tylenol was given. Crying lasted 6 hours and was inconsolable. No fever or other symtoms.
1.  Woke up the day after receiving the first dose without the ability to taste anything.  I could smell soaps/mint/fragrant lotions etc, if I sniffed it up close, but I could not taste anything. I tested this with several different  types of food.  This lasted until about 12:30 pm that day.  When I ate lunch I could taste my food again.   This was a strange event for me. I have never lost my sense of taste before.  2.  The evening of the third day after receiving the first dose of the moderna COVID-19 vaccine I experienced an approximate 4 inch diameter redness and itching around the injection site on my left shoulder.  There was also an itchy rash that extended across my chest and back to my right shoulder.  I took an antihistamine and went to bed.  When I awoke the next day the rash extending across my chest, back, and right shoulder was gone.  However, my left shoulder still  itched for the rest of that day.  The itchiness was gone when I awoke the next day.
Patient developed a local cellulitis at the site of injection starting on 7/26/17. The area of note was hot to touch, erythematous, skin was tight and tender on palpation. Treated with 10 day course of amoxicillin and f/u is prn if not improving.
No adverse effects; unspecified patients received improperly stored doses of PNEUMOVAX 23; This spontaneous report was received from a medical assistant, referring to a 68-year-old patient of unknown gender. No information regarding the patient's pertinent medical histories, concurrent conditions, concomitant therapies, drug reactions or allergies.  It was reported that on 09-OCT-2019, the vaccine pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) was exposed to a temperature excursion with a lowest temperature below 36 Fahrenheit (F) degrees (30.5 F degrees) for 10 hours. There was no previous temperature excursions.  On 01-NOV-2019, the patient was vaccinated with the improperly stored pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) lot # S029265, expiration date 31-MAR-2021 (dose, dose number, route of administration and anatomical injection site were not reported) for prophylaxis. The call was placed because of the Digital Data logger report. No adverse effects reported.  This is one of several reports received from the same reporter. combinationproductreport: Yes; brandname: PNEUMOVAX23 SYRINGE (DEVICE); commondevicename: Pneumococcal Vaccine, Polyvalent (23-valent); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. ; devicelotnumber: S029265; expirationdate: 31-MAR-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Unknown; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability; Sender's Comments:  US-009507513-1911USA001801: US-009507513-2005USA002426: US-009507513-2005USA002452: US-009507513-2005USA002453: US-009507513-2005USA002454: US-009507513-2005USA002456: US-009507513-2005USA002457:
Information has been received from a physician, for GARDASIL, a Pregnancy Registry product, concerning a female patient who on 09-DEC-2009 was vaccinated with a first 0.5 ml dose of GARDASIL (Lot # 662304/1013Y) and a second 0.5 ml dose of GARDASIL (Lot# 662299/1099Y) on 10-FEB-2010. On 17-FEB-2010 the patient was informed that she was pregnant after receiving two doses of GARDASIL. There was no adverse event reported. Follow-up information has been received from the physician concerning the female patient with polycystic ovarian syndrome, no significant past medical history and no previous pregnancies who on 09-DEC-2009 was vaccinated with a first 0.5 ml dose of GARDASIL (Lot # 662304/1013Y) and on 10-FEB-2010, the second 0.5 ml dose of GARDASIL (Lot# 662299/1099Y) was administered. Other medications used during this pregnancy were prenatal vitamins and fish oil supplements. Date of last menstrual period was 15-DEC-2009. Estimated delivery date on 06-OCT-2010. On 09-MAR-2010, an ultrasound was performed as routine and the result was well. On 08-MAY-2010, a Quad screen was performed and the result was "low high". Two more ultrasounds were performed on 23-APR-2010 and on 14-MAY-2010 and the results were also well. There were no complications during pregnancy, the diagnostics tests during pregnancy were within normal limits and there were no infections or illness during pregnancy. The patient had chorioamnionitis right before delivering. On 05-OCT-2010, the patient delivered a normal male baby, 41 weeks from LMP, weighing 7 lb 13.6 oz. Apgar score test was 8/9. There were not congenital anomalies or other complications. The patient's baby experienced papular rash on arms and back, cough, stuffy nose, dermatitis atopic, spitting a lot. White blood cell count abnormal, reticulocyte count abnormal, red cell distribution width increased, mean cell haemoglobin concentration abnormal, mean cell volume abnormal and jaundice after therapy with hepatitis B virus vaccine rHBsAg (WAES#1103USA03784). No further information is available.
Loss hearing in left ear and right ear pain. Eustachiam tube dysfunction in both ears.
Received Pfizer vaccines 1/28/21, 2/18/21 Tested positive for COVID by PCR on 12/13/21 Admitted to a local HCF 12/13-12/14/21 s/p fall w/ rib fractures, testing obtained upon admission.  Largely asymptomatic for COVID.
soreness and pain in the entire right arm, especially the deltoid muscle (injection site); fatigue; loss of appetite; intestinal cramping; loose stools
Narrative: COVID infection following COVID vaccine series unknown date and location. Pt had Pfizer vaccines. 12/24 SARS-COV-2 Variant Sequencing: pending 12/24 COVID swab, result: detected 12/24 pt admit cc: mild cough/runny nose dx: COVID 19 INFECTION LOS: 1 day 12/24 CXR impression: Lungs: Mild faint hazy opacity in the right medial lower lung zone which may represent early infectious or inflammatory process including COVID. Cardiomediastinal silhouette: No enlargement of the cardiomediastinal silhouette. Bones and soft tissues: Degenerative changes of the spine. 12/24 pt cc: cough exposure: unknown
Generalized itching onset after 10 minutes post-vaccination. Benadryl 50 mg PO and Pepcid 20 mg PO taken; symptoms improved. 12-18 hours later, noted moderate swelling of lips. Benadryl 50 mg PO repeated; symptoms improved.
patient received the vaccines fluzone HD and arexvy together on Wednesday 09/27/2023; pt did not experience reactions until Friday 9/29/23, at 1:30PM, patient felt paralized (cannot move her body except her head) and needed assistance from her husband to get out of bed; her joints were stiff to the point where she couldn't move on her own. This also occurred again at 1:30am; after discussion today, suggested taking tylenol and/or ibuprofen to help with the stiffness pain; she is feels better today but she still feels the stiffness in joint; she can walk a little better today but fears that she would feel paralyzed again
Child with urticaria starting within 5 mintues of vaccines sneezing, rhinorrhea with urticaria vomiting immediately after 5ml of benadryl given 20 mintues later gave 2.5 ml of benadryl with improvement of symptoms No wheezing @ 5, 10, 15 & 20 mintues
Patient had a small redness develop under her right eye. Over the course of a few days and keeping it clean, the rash got redder and spread to her left eye also. After 1 week with no improvement, we took her to hospital. The ER doctor treated her for blepharitis and impetigo. he prescribed ophthalmic bacitracin and said the rash should be clear in 2-4 days. After 5 days it was worse yet with a rash now developing on other areas of her body; neck, toes, bottom, stomach, cheek. We took patient to another hospital. By now her eyes were nearly swollen shut. The doctor recommended a possible food allergy, but we haven't given her anything new to try in 2 months. The doctor then said the rash may be environmental and released us with a dose of Benadryl. I teach Kindergarten and showed our school nurse my baby's rash and instantly she said she believed it to come from a vaccine allergy. This rash began exactly 2 weeks after patient's vaccines. We are giving her Benadryl per doctor's orders and letting the rash "run its course". After one day with the antihistamine we are seeing remarkable improvements.  We were informed today -now 10 days in- that the rash most likely came from the Tdap vaccine and it seems to be "common" according to the nurse. The 1st time she had this vaccine, she screamed the entire night and was fine the next day. The 2nd time she received this vaccine, she ran a very high fever of 103.2 on Tylenol, she was listless for the entire next day, and her pupils were constricted. This time she had the same reaction as her previous dose and now the rash.
Developed" Covid Arm"  9 days after vaccination. and lasted 6 days. Symptoms were itching, rash, redness and swelling from top of arm to elbow on outer right arm starting at the area of injection. No other symptoms
mom states put to bed aprox 8PM 2MAR93 & found lifeless @ around 6AM 3MAR93 EMS called;
Patient was given Booster dose too soon. Booster dose not indicated for those under 16 years old
Information has been received from a 78 year old female patient with no pertinent medical history and allergy to sulfonamides and meperidine hydrochloride who "2 months ago" on approximately 06-NOV-2010 was vaccinated with the first 0.5 ml dose, subcutaneously into the right upper arm of PNEUMOVAX 23 (Lot # not reported). There was no concomitant medication. The consumer reported that she developed soreness at the injection site of the right upper arm a few days after administration. The patient then developed throbbing at the injection site and a "burning feeling" at the right shoulder. On approximately 06-DEC-2010, one month after vaccination, the patient was evaluated by her physician. A "lump" on the top of the patient's right forearm was diagnosed as an enlarged lymph node. No therapy was prescribed but the physician was considering to referral to an unspecified orthopedic specialist. At the time of the report, the patient had not recovered. No laboratory tests were performed. The patient sought medical attention by visiting the physician's office. Follow up information received from patient's daughter who indicated that patient was still experiencing severe pain in her right arm at the PNEUMOVAX 23 injection site. No further information is available.
After about 10 minutes after vaccination patient complained of difficulty breathing, excessive sweating, numbness in hands and he was very pale. I called 911 and gave him one dose of epipen, Patient felt much better very quickly. Police and ems show up within a few minutes and stayed with him for about 45 minutes. He was fine and they cleared him. Neither he or ems felt it was necessary to transport him to the hospital. I called him later in the day and he was feeling fine.
Treatment of COVID-19; Treatment of COVID-19; Disease recurrence; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 75-year-old male patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Treatment of COVID-19"; DISEASE RECURRENCE (medically significant), outcome "unknown". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Negative, notes: Caller states 5 days after taking the medication, he was negative for the Covid virus; Positive, notes: Treatment: positive; Positive, notes: he tested positive again for Covid. Therapeutic measures were taken as a result of drug ineffective, covid-19. The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Post first injection only had sore arm next day. Post second injection had sore arm, fever that lasted ~36 hours, mild nausea that lasted only till mid morning day after, and headache lasting ~24 hours
Dizzy, lightheaded, weak, hot flashes, heart racing. Dizzy heart racing lasted 3 week. Other symptoms lasted 4 days.
CHILLS AND FEVER, FATIGUE, AND SEIZURE-LIKE CRAMPING THAT LASTED 2-3 MINUTES. CRAMPING RESOLVED AFTER DRINKING WARM WATER. SIDE EFFECTS EXPERIENCED 1/19/2022 AT AROUND 6:40AM
12 hours after second dose of Pfizer vaccine, I began to experience muscle aches that grew in severity over the next 8 hours. I also developed a fever and headache with bilateral eye pain and pressure. I was unable to sleep due to the pain as it was quite severe.
BODY ACHES; HEADACHES; BOTTOM LIP TWITCHING ON AND OFF; This spontaneous report received from a patient concerned a 28 year old male. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, and batch number: 1808986 expiry: UNKNOWN) dose was not reported, administered on 28-MAY-2021 for prophylactic vaccination. No concomitant medications were reported. On 28-MAY-2021, the subject experienced bottom lip twitching on and off. On 29-MAY-2021, the subject experienced body aches. On 29-MAY-2021, the subject experienced headaches. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from body aches, and headaches on MAY-2021, and had not recovered from bottom lip twitching on and off. This report was non-serious.
Pt developed fever and was seen with 15 lesions and dx'd with chickenpox.
Information has been received from a registered nurse concerning a "teenaged" female with pertinent medical history and drug reactions/allergies not specified who on an unspecified date was vaccinated with the first dose of GARDASIL. Concomitant suspect therapy included VARIVAX. Other concomitant therapy included HAVRIX, MENACTRA, TDAP.  Subsequently on an unspecified date, the patient experienced dizziness and almost fainted while on GARDASIL. Laboratory/diagnostic studies were reported as none. Unspecified medical attention was sought. ON a n unspecified date, the patient was recovering from the dizziness and almost fainted. No product quality complaint was involved. Additional information has been requested.
Pfizer-BioNTech COVID-19 Vaccine After receiving the vaccine, the vaccine recipient became nauseous/vomited in the bathroom and had a syncopal event. EMS evaluated and vaccine recipient was transported to the emergency room. The vaccine recipient symptoms improved and was discharged from the emergency room.
Resident placed three vaccines on patients left arm and one on the right arm leaving two vaccines to be given. Patient became dizzy and then fell back onto Dr. arms falling out of consciousness for approximately 10-15 seconds. Patient was placed laying down on the bench and was given juice. Patient remained laying down for another 10 minutes and then received the remaining two vaccines while laying down. After receiving final vaccines patient remained laying down for an additional 10 minutes. Patient was assessed by Dr. and was found to be alert and oriented without any dizziness.
The patient came into the clinic today requesting a COVID vaccine.  He completed an up to date Provider COVID-19 Immunization Consent Form that had been emailed to us from Health Department just this week.  He answered no to all the questions on the form so he was cleared to receive the vaccine.  We currently have Janssen.  The patient received his vaccination via proper procedures and left the clinic.  Upon entering his immunization into AR Web IZ it was noted that he had documentation of having the Moderna series.  The documenation showed one Moderna vaccine on 2-1-21 and the 2nd dose on 3-1-21.  The patient was contacted to verify that the WEB IZ account was his and to see if there had been a clerical error.  The patient confirmed that he had received the Moderna series and he confirmed that the dates sounded right.  The patient stated that he had lost his immunization card with proof of his Moderna vaccines and that he "thought it would be a good idea to just get vaccinated again so he would have proof."  Patient was made aware that he was already considered fully vaccinated before today's dose and that further vaccinations were not recommended.  Patient was made aware that due to the nature of the error and the vaccines being new that our clinic would have to reach out to other sources for guidance in this matter.  Spoke to patient about one hour after his vaccination and at that time he denied any side effects or issues.  Our state immunization department was made aware of the situation.
This is a spontaneous report from a non-contactable consumer.  A 27-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on 07Feb2021 at single dose for COVID-19 immunization at the age of 27-year-old. Medical history and concomitant medications were unknown. On 08Feb2021, the patient experienced soreness at injection site; no treatment given for the event. The patient recovered from the event. No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Headache, fever, chills, body aches, lethargy, fatigue Narrative:
Information has been received from a registered nurse concerning at least 2 or 3 patients who on unspecified dates completed series of RECOMBIVAX HB (adult) when they were young. But they had negative titer when they were tested for their college admission. In telephone follow-up, the registered nurse stated she did not remember the names of the patients involved, but would continue checking. Additional information has been requested.